TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05222126

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Hydrodissection (HD) with 5 cc 5% Dextrose
Description: The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 5 cc of 5% dextrose.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Hydrodissection (HD) with 5 cc Normal Saline
Description: The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 5 cc normal saline.
Study: NCT06003530

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hOMSC200
Description: Human Oral Mucosal Stem Cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hOMSC200
Description: Human Oral Mucosal Stem Cells

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Animal component-free, defined cryopreservation medium with 5% DMSO
Study: NCT05407246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemay005
Description: Hemay005 60 mg treatment group (group A): hemay005 tablets 60 mg bid were used during the treatment period; Hemay005 75 mg treatment group (group B): hemay005 75 mg bid was used during the treatment period; Placebo group (Group C): placebo (hemay005 tablet simulant) bid was used during the treatment period;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemay005
Description: Hemay005 60 mg treatment group (group A): hemay005 tablets 60 mg bid were used during the treatment period; Hemay005 75 mg treatment group (group B): hemay005 75 mg bid was used during the treatment period; Placebo group (Group C): placebo (hemay005 tablet simulant) bid was used during the treatment period;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hemay005
Description: Hemay005 60 mg treatment group (group A): hemay005 tablets 60 mg bid were used during the treatment period; Hemay005 75 mg treatment group (group B): hemay005 75 mg bid was used during the treatment period; Placebo group (Group C): placebo (hemay005 tablet simulant) bid was used during the treatment period;
Study: NCT05946538

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SARS-COV-2, Influenza and RSV 8-Well MT-PCR Panel
Description: The SARS-CoV-2, Influenza and RSV PCR test is multiplex-tandem polymerase chain reaction (MT-PCR) based on qualitive in vitro diagnostic testing for the detection and identification of pathogens in nucleic acid extracts.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: BioFire Respiratory Panel 2.1
Description: The BioFire Respiratory Panel 2.1 (RP2.1) is a PCR-based multiplexed nucleic acid test intended for use with the BioFire® FilmArray® 2.0 or BioFire® FilmArray® Torch Systems for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of respiratory tract infections.
Study: NCT05222126

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Hydrodissection (HD) with 10 cc 5% Dextrose
Description: The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 10 cc 5% dextrose.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Hydrodissection (HD) with 10 cc Normal Saline
Description: The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 10 cc normal saline.
Study: NCT06141876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APEX-002-A02
Description: Active

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT05495165

Intervention type: OTHER
Group type: OTHER
Intervention: Therapeutic education for patients in nutrition
Description: Stakeholders give preventive therapeutic education recommandations in their specific expertize
Study: NCT05186506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensatinib
Description: 225 mg administered once daily orally for two years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Pemetrexed : Participants will receive 500 mg/m\^2, day 1 , Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~Cisplatin :Participants will receive 75 mg/m\^2, day 1 , 21 days/cycle, Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~Paclitaxel: Participants will receive 175 mg/ m\^2, day 1 , 21 days/cycle, Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~carboplatin AUC= 5 mg/ mL/min, intravenously guttae, day 1 ,Q21D ，until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
Study: NCT04688255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MSTEP
Description: Aerobic exercise that is advanced weekly

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Stretching exercises that are advanced weekly
Study: NCT05691114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAESCs
Description: human Amniotic Epithelial Stem Cells
Study: NCT06366360

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immersive Virtual Reality Intervention
Description: The immersive virtual reality rehabilitation protocol is an experimental protocol based on musical practice. This protocol will be based on the Piano Vision application, which allows several modes of music production: free or guided musical practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immersive Virtual Reality Intervention
Description: The immersive virtual reality rehabilitation protocol is an experimental protocol based on musical practice. This protocol will be based on the Piano Vision application, which allows several modes of music production: free or guided musical practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: The conventional rehabilitation corresponds to the classically performed in the cognitive treatment of unilateral spatial neglect. It involves training visual scanning using barrage exercises, sequence identification, scene description, and pointing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: The conventional rehabilitation corresponds to the classically performed in the cognitive treatment of unilateral spatial neglect. It involves training visual scanning using barrage exercises, sequence identification, scene description, and pointing.
Study: NCT04984382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized training on Helicobacter pylori eradication treatment
Description: Standardized training on Helicobacter pylori eradication treatment
Study: NCT06442670

Intervention type: DEVICE
Intervention: Electroencephalography
Description: Phase synchrony during the completion of the semantic memory task

Intervention type: DEVICE
Intervention: Electroencephalography
Description: Phase synchrony during the completion of the semantic memory task

Intervention type: DEVICE
Intervention: Electroencephalography
Description: Phase synchrony during the completion of the semantic memory task

Intervention type: DEVICE
Intervention: Electroencephalography
Description: Phase synchrony during the completion of the semantic memory task
Study: NCT05327868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat Diet (LFD)
Description: Subjects will be asked to adhere to a low fat diet (assigned in random order) and be counseled by a dietitian using 5 days of sample menus, monitored online using a shared nutrient analysis program, and supplied with low fat foods to increase compliance
Study: NCT06442670

Intervention type: DEVICE
Intervention: Electroencephalography
Description: Phase synchrony during the completion of the semantic memory task
Study: NCT05177367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequential Variety
Description: 3 courses each consisting of a different food

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequential Variety
Description: 3 courses each consisting of a different food

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simultaneous Variety
Description: 3 courses each consisting of 3 foods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simultaneous Variety
Description: 3 courses each consisting of 3 foods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single Food
Description: 3 courses each consisting of the same food

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single Food
Description: 3 courses each consisting of the same food

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small portion
Description: Small meal portion size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small portion
Description: Small meal portion size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small portion
Description: Small meal portion size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large Portion
Description: Large meal portion size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large Portion
Description: Large meal portion size
Study: NCT05177367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large Portion
Description: Large meal portion size
Study: NCT05327868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Diet (HFD)
Description: Subjects will be asked to adhere to a high fat diet that is rich in SFAs (assigned in random order) and be counseled by a dietitian using sample 5 days of menus, monitored online using a shared nutrient analysis program, and supplied with high fat foods to increase compliance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Diet (HFD)
Description: Subjects will be asked to adhere to a high fat diet that is rich in SFAs (assigned in random order) and be counseled by a dietitian using sample 5 days of menus, monitored online using a shared nutrient analysis program, and supplied with high fat foods to increase compliance
Study: NCT05417581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adipose surgery
Description: A quantity of adipose tissue equivalent to 10-20 cubic centimeter will be removed subcutaneously and from the omentum during surgical procedures (oncological, bariatric)
Study: NCT04766411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unresisted sprint training
Description: Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resisted sprint training with load equal to 10% of body weight
Description: Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resisted sprint training with load equal to 20% of body weight
Description: Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint
Study: NCT05483556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real tDCS
Description: An anodal high-definition tDCS of 2 mA lasting for 20 minutes will be delivered to the left inferior frontal gyrus during speech therapy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: An anodal high-definition tDCS of 2 mA lasting for 30 seconds will be delivered to the left inferior frontal gyrus during speech therapy.
Study: NCT04417231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRP apheresis
Description: Selective CRP apheresis by use of the PentraSorb-CRP
Study: NCT06202040

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Oblique Subcostal Transversus Abdominis Plane Block (OSTAP) will be performed.
Description: The OSTAP block will be conducted in-plane using a 100mm 22 G needle and a linear probe under ultrasound (USG) guidance. The 20cc block will contain 10cc of 0.5% bupivacaine and 10cc of normal saline. Bilateral OSTAP will be administered with 20cc (10cc per side). To apply the block, position the linear probe parallel to the rib edge immediately below it on the anterior abdominal wall. Visible will be the external, internal, transversus abdominis, and rectus muscle junction. The needle tip will move toward the TAP space (between the internal oblique and transversus abdominis muscles). To ensure medication delivery, the needle tip will be visible in the TAP and the drug will be aspirated negatively. USG will also observe drug distribution at the rectus abdominis muscle-TAP space junction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Rectus Sheath Block (RSB) will be performed.
Description: When the patient is in the supine position, the ultrasound (USG) linear probe is held in the transverse plane at the level just above the umbilicus, where the posterior rectus sheath is best visualized. Using the in-plane technique with a 100mm 22 G needle under USG guidance, the drug prepared will be administered between the rectus muscle and the posterior rectus sheath. For this block, a volume of 20cc will be prepared, consisting of 10cc of 0.5% bupivacaine and 10cc of normal saline. Bilateral Rectus Sheath Block (RSB) will be applied with a total volume of 20cc, 10cc to each side.
Study: NCT05681390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg iv drip, d1, Q3W;Anlotinib tablet : 10mg, PO, QD; Chemotherapy: selected by investigator following CSCO or NCCN pancreatic adenocarcinoma guideline; Tislelizumab and Anlotinib continue unless disease progression or intolerance to toxicity, chemotherapy continue upto 8 cycles unless disease progression or intolerance to toxicity
Study: NCT04934657

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04766411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control trial
Description: Participants will not perform any sprint training protocol
Study: NCT06171828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Head-Mounted Display (HMD) to communicate with a supervisor remotely
Description: Participants in the experimental group are oriented on using the education platform and communicating with the supervisor through an HMD for about 5 minutes. They then perform and save their ultrasound imaging. If they require assistance, they request help verbally through the HMD's communication system. The supervisor remotely observes and immediately assists upon request, utilizing the HMD and a 360-degree camera.
Study: NCT05162313

Intervention type: DEVICE
Group type: OTHER
Intervention: confirmation of endotracheal tube positioning
Description: After performing the tube insertion by direct laryngoscopy, videolaringoscopy or fiberoptic technique, the attending neonatologist will connect both the colorimetric capnometer and the proximal flow-sensor to the tracheal tube. If the flow sensor is not proximal but incorporated into the mechanical ventilator, the care provider will connect the capnometer only. During the procedure, the information given by the capnometer will be evaluated by the care provider performing the intubation, while the flow sensor information will be monitored only by a study investigator, who will not reveal any details to the care provider. In particular, the yellow color change by the capnometer and the presence of exhalation flow curves on the ventilator screen will be considered as confirmation of correct tracheal tube positioning, respectively.
Study: NCT05987956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib - Usual
Description: Usual Alectinib Chemotherapy (NDC...01)~- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib - Study
Description: Study Alectinib Chemotherapy (NDC...86)~- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily
Study: NCT06095609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilization plus chest physiotherapy
Description: Early mobilization:early mobilization has been confirmed its positive effectiveness on cutting down the MV use days and mortality rate, attenuating the side effect such as muscle strength loss and functional activity dysfunction resulting from ICU acquired weakness among the patients with mechanical ventilation.~Chest physiotherapy:a common technique to reduce the respiratory complications in ICU, has been proved certain positive influence on airway clearance and hospital lengths of stay.
Study: NCT04707300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human T Lymphoid Progenitor (HTLP) injection
Description: The HTLP cell suspension will be injected intravenously at the time of UCB HSCT on D0
Study: NCT05809063

Intervention type: OTHER
Intervention: observational
Description: document the number , disease pattern\& outcome of neonates admitted to the neonatal intensive care units

Intervention type: OTHER
Intervention: observational
Description: document the number , disease pattern\& outcome of neonates admitted to the neonatal intensive care units

Intervention type: OTHER
Intervention: observational
Description: document the number , disease pattern\& outcome of neonates admitted to the neonatal intensive care units

Intervention type: OTHER
Intervention: observational
Description: document the number , disease pattern\& outcome of neonates admitted to the neonatal intensive care units

Intervention type: OTHER
Intervention: observational
Description: document the number , disease pattern\& outcome of neonates admitted to the neonatal intensive care units

Intervention type: OTHER
Intervention: observational
Description: document the number , disease pattern\& outcome of neonates admitted to the neonatal intensive care units

Intervention type: OTHER
Intervention: observational
Description: document the number , disease pattern\& outcome of neonates admitted to the neonatal intensive care units
Study: NCT06388603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioactive Glass
Description: Bonalive Granules and Bonalive Putty will be used (according to their IFU and CE certification) to fill the bone void after the debridment of infected tissue as they have osteoconductive and osteostimulative properties that allow bone rigeneration. Moreover, Bonalive Granules also present some bacteria growth inhibiting properties to combact bone infection propoer of Ostemyelitis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The investigators are left free to proceed according to the normal standar procedure they normally use. The procedures can vary according to investigator judgment also depending on the state of Osteomylitis.
Study: NCT06169280

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NSC-CRAd-S-pk7
Description: NSC-CRAd-S-pk7 1·50 x 10⁸ NSCs loaded with1·875 x viral particles administered intra-tumorally on Day 0 and Day 15, then every 4 weeks for up to 6 total doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NSC-CRAd-S-pk7
Description: NSC-CRAd-S-pk7 1·50 x 10⁸ NSCs loaded with1·875 x viral particles administered intra-tumorally on Day 0 and Day 15, then every 4 weeks for up to 6 total doses.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine amide (NACA)
Description: N-acetylcysteine amide (NACA) 600 mg oral, is taken daily from registration to just prior to dose 2 of NSC-CRAd-S-pk7.
Study: NCT06168487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Patients will be given telmisartan alone or with standard of care chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Patients will be given telmisartan alone or with standard of care chemotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care Regimen
Description: Standard of Care Regimen
Study: NCT06140095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: See arm description
Study: NCT04227821

Intervention type: OTHER
Intervention: Vasopressor and/inotrope therapy
Description: In pediatric patients admitted to the pediatric intensive care, with the persistent hemodynamic instability after fluid resuscitation, the vasopressor and/or inotrope therapy will be initiated
Study: NCT05111977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrant capsule
Description: A capsule delivering mechanical vibrations

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Vibrant capsule
Description: A capsule delivering mechanical vibrations
Study: NCT04540289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT)
Description: Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2016 ESC guidelines for the management of acute and chronic heart failure
Study: NCT05180175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Top down treatment if patient at high risk
Description: Patients with an increased risk of poor disease course (as defined by a serum protein signature at diagnosis), will be treated with a top down treatment strategy.
Study: NCT06264856

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchoscopic sputum suction
Description: Bronchoscopy is a medical procedure in which a flexible tube called a bronchoscope is passed through the mouth or nose and into the lungs. Bronchoscopic suction is a technique used during bronchoscopy to remove secretions, mucus, or foreign objects from the airways.~The bronchoscope is equipped with a suction port and a suction channel that allows the doctor to remove fluids or other material from the airways. The suction port is connected to a vacuum source, and the suction channel runs through the bronchoscope and terminates at the tip of the instrument.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: negative pressure aspiration suction
Description: The procedure involves inserting a catheter into the airway and applying negative pressure to the catheter to suction out the secretions or fluids. The patient could receive sputum suction as medical routine (every 2-4 hrs) if needed.